Bio­Marin CEO JJ Bi­en­aimé is plan­ning for a block­buster fu­ture in the gene ther­a­py biz: to the tune of $10B to $15B a year

The eco­nom­ics of gene ther­a­py has cap­tured just about every­one’s at­ten­tion in the in­dus­try. This first wave is faced with stub­born ques­tions about dura­bil­i­ty, the race to first-in-class sta­tus as well as the sticky is­sue of just how much mon­ey you can make from these sup­pos­ed­ly once-and-done ther­a­pies that can cure pa­tients of some ter­ri­ble dis­eases.

Bio­Marin CEO Jean-Jacques Bi­en­aimé felt the full force of that blow­back from a range of an­a­lysts in yes­ter­day’s Q4 call. And at one point in the con­ver­sa­tion, he of­fered a snap­shot of what the fu­ture could look like — and it’s a big one.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.